Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KEROS THERAPEUTICS INC.
KROS | US
10.55
USD-0.35
-3.21%
KROS | US
About KEROS THERAPEUTICS INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
10.55
Open
10.96
High
11.11
Low
10.48
Keros Therapeutics Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes novel treatments for patients suffering from hematological pulmonary and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050 which is being developed for the treatment of low blood cell counts or cytopenias including anemia and thrombocytopenia in patients with myelodysplastic syndromes as well as in patients with myelofibrosis. It also develops KER-047 a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012 which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics Inc. was incorporated in 2015 and is headquartered in Lexington Massachusetts.
View LessKROS | US
Risk
59.9
Sharpe
-0.64
Luna's Score
43/100
Recommendation
Sell
Luna says (KROS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
64.4%1 month
59.9%3 months
59.1%6 months
55.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.45
Debt to equity
0.03
Debt to assets
0.03
Ent. to EBITDA
-13.05
Ent. to rev.
7.01K
PEG
-
Other Fundamentals
EBITDA
-187.62M
MarketCap
395.86M
MarketCap(USD)
395.86M
Div. yield
-
Op. margin
-136.32K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-44.98
Short ratio
7.41
Short perc.
11.28
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.84
Range1M
2.42
Range3M
4.05
Volumes: Market Activity
Rel. volume
0.88
Price X volume
3.27M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -13.05 | - | Cheaper |
| Ent. to Revenue | 7,012.25 | - | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.45 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 59.07 | - | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 395.86M | - | Emerging |
